Developments Zevra receives FDA approval for Miplyffa to treat NPC Zevra Therapeutics (NASDAQ:ZVRA), has announced FDA approval for its Miplyffa oral capsules, used in combination with miglustat, for the treatment of Niemann-Pick disease C (NPC) in adult and pediatric patients aged two... September 23, 2024